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Abstract: Commercially available domperidone orodispersible tablets (ODT) are intended for 
immediate release of the drug but none of them have been formulated for sustained action. The 
aim of the present research work was to develop and evaluate orodispersible sustained release 
tablet (ODT-SR) of domperidone, which has the convenience of ODT and benefits of controlled 
release product combined in one. The technology comprised of developing sustained release 
microspheres (MS) of domperidone, followed by direct compression of MS along with suitable 
excipients to yield ODT-SR which rapidly disperses within 30 seconds  and yet the dispersed MS 
maintain their integrity to have a sustained drug release. The particle size of the MS was optimized 
to be less than 200 μm to avoid the grittiness in the mouth. The DSC thermograms of MS showed 
the absence of drug-polymer interaction within the microparticles, while SEM confirmed their 
spherical shape and porous nature. Angle of repose, compressibility and Hausner’s ratio of the 
blend for compression showed good flowability and high percent compressibility. The optimised 
ODT-SR showed disintegration time of 21 seconds and matrix controlled drug release for 9 h. In-
vivo pharmacokinetic studies in Wistar rats showed that the ODT-SR had a prolonged MRT of 
11.16 h as compared 3.86 h of conventional tablet. The developed technology is easily scalable 
and holds potential for commercial exploitation. 




Oral tablets have been the most popular and successfully used dosage form for delivery of drugs 
because of the convenience for use, ease of administration, simplicity in production and low cost 
of such systems. However, problems may arise in the administration of tablets to patients who 
have difficulty in swallowing, for example children, elderly people or more seriously ill patients.  
Orodispersible tablet (ODT) is good for such subpopulations, in general for paediatric and geriatric 
patients1 or patients with swallowing dysfunction or dysphagia2. ODTs  disintegrate in the oral 
cavity within seconds and are washed out with saliva without the need of liquid3. These tablets are 
also suitable for those who are travelling and do not have easy access to water, mentally ill, 
bedridden and patients with persistent nausea4-6. It is also useful for the patients, where the 
underlying disease disrupts swallowing ability (e.g. migraine, Parkinson’s disease)7-9. Studies have 
shown distinct patient preference for ODTs over regular tablets in certain disease conditions10-12. 
 
ODTs by virtue of their fast disintegration are meant for immediate release of drug. Though these 
tablets cater to patients with swallowing difficulties and other patient needs as outlined above 
however, they are required to be administered frequently, depending upon the biological half-life 
of the drug and may lead to poor patient compliance. This limitation can be overcome by designing 
sustained release (SR) or controlled release drug delivery system13-15. The current sustained release 
technologies can be exploited and incorporated into an ODT to improve their functionality 
reducing need of multiple dosing regimens, improving patient adhereance, provide predictable and 
reproducible drug release, maintain steady drug plasma levels and reduce dose-dependent side 
effects associated with the repeated administration16. 
 Domperidone (5-chloro-1-[1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidine-4-
yl]-1,3-dihydro-2H-benzimidazol-2-one; (Figure 1), is a weak base (pKa=7.89), practically 
insoluble in water and with a lipid to water ratio (log P) of 3.9017. It is a potent drug exerting its 
gastrokinetic action by acting on the peripheral dopamine.sub.2 receptors in the GIT and is a 
unique compound with both gastrokinetic and antiemetic activity18,19. Unlike metoclopramide, 
another dopamine-receptor antagonist, domperidone does not readily cross the blood-brain barrier; 
therefore it has rather minimal extrapyramidal side effects. Clinically, domperidone has been 
shown to be useful in the treatment of various gastric motility disorders, namely chronic and 
subacute gastritis, to prevent GI symptoms associated with the use of dopamine agonists in 
Parkinson's disease, in diabetic gastroparesis, in anorexia nervosa and in patients with 
postvagotomy gastroparesis20. Commercially available orodispersible domperidone tablets are 
meant for immediate release of the drug and are given 3-4 times a day due to the short half-life   
( ~7 h).  
One of the approaches to prepare controlled release formulations is the use of microsphere (MS) 
or microparticles of drug-polymer composites, where the active ingredient is distributed in the 
polymer matrix21,22. The polymeric matrix allows for slow, controlled and predictable drug release 
over a period of time and hence reduces the overall amount of drug needed to be incorporated23,24. 
The present work reports development of orodispersible sustained release tablets (ODT-SR) of 
domperidone which includes, first the preparation of sustained release MS of domperidone which 
were then compressed along with suitable excipients to give orodispersible sustained release tablet 
with the desired characteristics. This tablet is intended to disintegrate rapidly within the mouth into 
microspheres which will deliver the drug in a sustained manner after swallowing. For better 
patient-compliance, after disintegration of the tablet in the mouth, the disintegrated material should 
be small in particle size, so that patients do not feel the unpleasant grittiness of bigger particles. 
The maximum particle size with which patients do not feel the sandy feeling or rough sensation 
on the tongue is around 200 µm, so the particle size of MS was envisaged to be less than 200 µm 
to avoid any rough mouth feel25. Such a formulation would have all the advantages and 
convenience of ODT dosage form and would simultaneously provide sustained release of the drug. 
Furthermore, although orodispersible tablet with sustained release properties is reported26-29 
incorporating MS prepared by emulsion solvent evaporation technique into ODT has not been 
investigated. MS of domperidone are very easy to prepare by this emulsion solvent evaporation 
technique and can be beneficial commercially. 
Materials and Methods 
Materials 
Domperidone was obtained as a gift sample from Ipca laboratories Ltd, Mumbai. Avicel (FMC 
Biopolymer), Pearlitol 200 SD (Roquette), lactose, Polyplasdone XL-10, sodium saccharine, 
magnesium stearate (Ferro), Aerosil 200 were received as gift samples  from Signet Chemicals, 
Mumbai. Ethocel Std. 10 was a gift sample from Dow, India. Directly compressible 
microcrystalline cellulose (Avicel PH- 102, particle size ~100 µm) was gift from FMC 
Biopolymers, India. Ethanol, Span 80, liquid paraffin and n-hexane were purchased  from S.D. 
Fine chemicals, Mumbai. Domilon-MD® (Senate Labs) and Domperi- 10® (Saorite 
Phamracetuicals) were purchased from a local pharmacy in Mumbai. 
 
Methods  
Formulation of  ODT-SR  
Formulation of  ODT-SR involved two steps: 
a) Preparation and characterization of sustained release MS of domperidone 
b) Preparation of ODT-SR incorpoarating domperidone MS 
Preparation of Sustained Release microspheres 
MS of domperidone were prepared by emulsion solvent evaporation method30,31. Formulations 
were prepared by varying drug: polymer ratios. Drug and polymer were dissolved in ethanol. The 
above mixture was added dropwise with help of syringe in light liquid paraffin and stirred at 2000 
rpm for four hours. The formed MS were vacuum filtered and then freed from liquid paraffin by 
repeated (2-3 times) washing with n-hexane and further the product was air dried over a period of 
12 h to remove completely the traces of n-hexane and sieved through US sieve no. 70. Optimization 
studies were conducted to investigate the effect of formulation variables on characteristics of 
domperidone MS. A randomized 32 full factorial design was used to optimize the effect of two 
input variables i.e. polymer concentration (X1) and drug concentration (X2) in the MS on three 
response variables i.e. mean particle size, percent yield and percent drug entrapment (Table 1a). 
Characterisation of Domperidone Microspheres 
a) Particle Size 
Particle size of the MS were characterized using optical microscopy (Olympus microscope, India).  
Measurement of 200 microspheres was taken and mean particle size and particle size distribution 
were determined32.  
b) Calibration Curve of the Domperidone 
As domperidone is poorly soluble in water, organic solvent is required to solubilize the drug. 
Therefore, stock solution of domperidone was prepared in methanol and working standards were 
prepared by suitably diluting with 0.1M HCl and the absorbance were measured using UV-Vis 
Spectrophotometer (Jasco, MD, USA) at λmax 287 nm against blank. Calibration curve was 
plotted between drug concentration (2-20 μg/ml) and absorbance for each of the working 
standards. 
c) Drug Entrapment Efficiency  
A weighed quantity of MS were crushed into powder and added to 100 ml of 0.1 M Hydrochloric 
acid (HCl). The resulting mixture was kept stirring at 1000 rpm for 2 h. Then the solution was 
filtered through membrane filter of 0.45 µm pore size and 1 ml of this solution was diluted using 
0.1 M HCl and analyzed for domperidone content using  UV Spectrophotometer at λmax of 287 
nm. The drug entrapment efficiency was calculated using the following equation:                                                       
 





d) Percent Yield 
The prepared MS were collected and weighed. The weight obtained was divided by the total 
amount of all non-volatile components which were used for the preparation of the MS. 
% 𝑌𝑖𝑒𝑙𝑑 =
𝐴𝑐𝑡𝑢𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑝𝑟𝑜𝑑𝑢𝑐𝑡
𝑇𝑜𝑡𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑒𝑥𝑐𝑖𝑝𝑖𝑒𝑛𝑡𝑠 𝑎𝑛𝑑 𝑑𝑟𝑢𝑔 
× 100 
e) Scanning Electron Microscopy (SEM) 
The surface characteristics of drug loaded MS were examined by means of a scanning electron 
microscopy. The MS were coated with gold or palladium under vacuum using a sputter coater  and 
then samples were examined under the scanning electron microscope (Philips XL 30 SEM) setup 
at 10kv with a till of 45. Using suitable magnification SEM micrographs of domperidone loaded 
MS were recorded. 
f) Differential Scanning Calorimetry (DSC) 
Drug-polymer interactions were studied by DSC (Q 2000 TA Instruments) analysis. The DSC 
analysis of pure domperidone, ethyl cellulose and domperidone MS was carried out by heating 
samples in the range of 30 to 340 0C at a rate of 10 0C min -1 and the thermograms were recorded. 
g) In-vitro Drug release 
100 mg of drug loaded MS were tied in nylon cloth and kept in the basket which was then immersed 
in the dissolution medium (0.1 M HCl, 900 ml) and stirred at 100 rpm using USP dissolution 
Apparatus II (Electrolab EDT-08Lx). 5 ml of aliquots of medium were removed after 30 min, 1, 
2, 3, 4, 5, 6, 7, 8, 9, and 10 h respectively, each aliquots being replaced simultaneously by an equal 
volume of medium to maintain constant volume. The amount of domperidone was determined 
spectrophotometrically using  UV spectrophotometer at λmax 287 nm. The test was carried out in 
triplicate. The amount of drug released was calculated using standard calibration curve of the drug 
in 0.1 M HCl. The drug release profiles for various MS formulations were plotted as the percent 
of domperidone released from the MS vs. time and further studied for the release kinetics.  
h) Drug Release Kinetics 
 To determine the mechanism of drug release from MS, data were subjected to further analysis. 
The data were fitted to zero order (equation 1), first order (equation 2) and Higuchi’s matrix 
diffusion controlled (equation 3) kinetics33,34. 
Qt = Q0 - K0t ……………................Equation 1 
log Qt = log Q0 – K1t/2.303 ………...Equation 2 
Qt = KHt1/2 .........................................Euation 3 
Where, Qt is the amount of drug released in time t, Q0 is the initial amount of the drug in the 
solution, K0 is the zero order release rate constant, K1 is the first order release rate constant, KH is 
the Higuchi diffusion rate constant, and geometrical characteristics of the tablets.  
Formulation and Evaluation of ODT-SR 
The formulation of ODT-SRs involved preparation and evaluation of dry blend of MS with suitable 
excipients for compression followed by direct compression into tablets. 
Preparation and Physical Characterization of Blends Ready for Compression 
MS were dry blended in a tumbling cylindrical blender with suitable excipients like mannitol 
(diluent), lactose (diluent),  microcrystalline cellulose (diluent) crospovidone, (super disintegrant),  
magnesium stearate (lubricant), sodium saccharine (sweetner) and Aerosil (glidant)  to prepare 
seven batches (F1-F7) with various compositions (Table 2). The blends ready for compression 
were evaluated for various physicochemical characteristics such as angle of repose, bulk density, 
tapped density, percent compressibility and Hausner’s ratio.  
Preparation and Evaluation of ODT-SR  
A single punch tablet compression machine (Cadmach Company, India), equipped with flat faced 
punches with a die diameter of 8 mm was employed to prepare tablets with an average weight of 
200 mg. ODT-SRs were evaluated for the following parameters: 
a) Uniformity of Mass for Single-dose Preparations 
The individual and average weight of 20 tablets from each batch was determined using an 
electronic balance and conformity to uniformity of mass test for tablets for each batch was 
established35. The average mass was expressed in mg ± S.D. 
b) Thickness of Tablets  
Thickness of tablets was assessed using a Vernier caliper (Fisher Scientific, USA).  
c) Hardness  
The Monsanto hardness tester was used to measure the crushing strength of the tablets. The average 
hardness (mean of three determinations) was calculated.  
d) Drug Content 
Domperidone content in the ODT-SR was determined. Briefly, 20 tablets were selected randomly 
and triturated with the help of morter and pestle. The amount equivalent to weight of one tablet 
was weighed and domperidone content was determined using UV-Vis Spectrophotometer at λmax 
287 nm against blank. 
e) Friability 
 According to European Pharmacopoeia35, sample of twenty tablets was accurately weighed and 
placed in the drum of tablet friability tester (Electrolab EF-1W India) revolving at 25 rpm for 4 
min. At the end of the 100 rotations, the tablets were removed, dusted and reweighed to determine 
the loss in the weight of the tablets.. The percentage friability was determined using the following 
equation:       






f) Disintegration Time 
The mean disintegration time for six ODT-SRs were determined in seconds (±S.D). 
g) In-vitro Drug Release 
In-vitro drug release from ODT-SR  was studied using USP type II dissolution test apparatus 
(Electrolab EDT-08Lx) in 900 ml of 0.1 M HCl maintained at 37 ± 0.5 0C  with paddle speed of 
rotation of 100 rpm. Domperidone content was analyzed at λmax of 287 nm using  UV-Vis 
spectrophotometer. 
h) Stability Study 
The stability of the developed ODT-SR was conducted for 12 weeks. Optimized formulation (F4) 
was selected for the stability study. Briefly, samples were stored in the sealed aluminium pouch at 
25°C/60% RH and at 40°C/75% RH. Samples were analyzed for appearance, domperidone content 
and drug release profile during the stability study duration of 12 weeks.  
i) InVivo Pharmacokinetic Study 
Pharmacokinetic study of optimized ODT-SR (F4) was carried out in Wistar rats after oral 
administration and compared with a conventional marketed domperidone tablet (OC2). The 
protocol of the study was approved by the Institutional Animal Ethics Committee of C.U.Shah 
College of Pharmacy,  SNDT Women’s University, Mumbai.   
 
i) Animal Specification 
Wistar rats weighing about 180-220 g were used for the study. Animals were fed with a standard 
pelletised diet and were given free access to water. 
ii) Drug Administration and Collection of Plasma 
The ODT-SR of domperidone was administered orally at a single dose of 1.64 mg/ 200 g body 
weight after dispersing it in normal saline36. Necessary corrections were made and the animal 
dosage was determined from the human dose using the conversion factor37. An identical dose was 
given for the marketed domperidone tablet. The marketed domperidone tablet was grinded and 
dispersed in 1.5 ml of  0.5% (w/v) carboxymethylcellulose–sodium (CMC–Na) solution and tablet 
suspension was administered to rat by oral gavage38. After administration of the formulations, 
blood was withdrawn using the sparse withdrawal technique at suitable intervals of 0.5, 1, 2, 4, 6, 
8, 10, 14, 15 and 24 h from the retro-orbital plexus of the rat eye. For withdrawal of blood from 
retro-orbital plexus, the animals were exposed to chloroform vapors and made unconscious 
temporarily and the blood was withdrawn using fine capillary and collected in a test tube 
containing 0.3% sodium citrate solution as an anticoagulant. Blood was centrifuged for 10 minutes 
at 3000 rpm. The supernatant layer of plasma was separated by micropipette and was stored at -
20ºC until further analysis. 
iii) Extraction of Drug from Plasma 
To 500 µl of plasma, 1.5 ml of acetonitrile was added and vortexed for 3 minutes, followed by 
centrifugation at 3000  rpm. After centrifugation, supernatant layer of acetonitrile was carefully 
separated and analyzed using a validated HPLC method. 
iv) Chromatographic Conditions 
Analysis of domperidone in plasma samples was carried out by reverse phase  HPLC (Aigilent 
Technologies 1200 series). The chromatography was carried out using C-18 column (25cm × 4.5 
mm, 0.5 µm) at 287 nm wavelength (λ) with a mobile phase of buffer (pH 7.4):acetonitrile (2:1) 
at flow rate of 1ml/min. The injection volume was kept constant at 10µl and run time was 
maintained for 20 minutes. 
v) Pharmacokinetic Analysis 
Standard methods39 were used to calculate the pharmacokinetic parameters such as area under the 
drug-concentration time-curve (AUC), half- life (t1/2) and mean residence time (MRT) using non-
compartmental analysis. The maximum plasma concentration of drug (Cmax) and time to reach 
Cmax (Tmax) were directly computed from the plasma concentration vs. time plot.  
 
 
f) Statistical Analysis 
Statistical comparisons of the experimental results were performed by one-way analysis of 
variance (ANOVA) at an alpha level of 0.05. The difference in results between the 2 groups was 
compared by Tukey-Kramer multiple comparison test at the significance levels of P < 0.05. 
 
Results and Discussion 
Domperidone Loaded Microspheres 
a) Preparation of Microspheres       
Ethyl cellulose was used as the polymer for the preparation of sustained release MS. Ethyl cellulose 
solution at a level of 0.5% w/v or less was not viscous enough to form and/or sustain the formed 
micro droplets, which is essential for the formation of MS. On the other hand, the polymer solution 
was found to be too viscous to pass through syringe when used at 3% w/v concentration level and 
did not yield droplets of desirable size for preparation of MS, but rather resulted in the formation 
of large aggregates. Therefore, three polymer concentrations, greater than 0.5% w/v and less than 
3% w/v viz. 1.5, 2 and 2.5% w/v were investigated for the optimization of preparation of MS along 
with the second input variable, drug concentration using 32 factorial designs and their effect on the 
mean particle size, percent yield, and percent drug entrapment was observed. 
It was observed that with the increase in polymer concentration from lower level (X1,-1) to higher 
level (X1, +1), at all three drug levels (X2, -1, 0 and +1) resulted in the increase in the mean particle 
size of MS from 58 to 196 µm. This increase in particle size may be because of the increase in 
viscosity of the droplets due to the increased polymer concentration. The increase in viscosity was 
high enough to result in difficulty in dispersion and subdivision of the droplets. Similar effects 
have been reported for ethylcellulose MS prepared by water-in-oil-in-oil double emulsion solvent 
diffusion technique40. Increase in drug concentration from lower level (X2, -1) to higher level (X2, 
+1) also resulted in increase in mean particle size of the MS. Increase in mean particle size with 
the increase in the drug concentration may also be because of the increase in viscosity of the 
droplets present in the internal phase caused by the increased drug concentration. 
Polymer concentration at medium level (X1, 0) and domperidone at the highest level (X2, +1) 
yielded MS with the highest drug entrapment (74%) as well as highest percent yield (86%). When 
X1 was set at the medium level (0) and X2 was set either at the lower (-1) or at the medium level 
(0), less than 74% of the drug was found to load in the MS and also resulted  in lower percent 
yield. 
The effects of the input variables on the % drug entrapment, particle size and percent yield of 
domperidone ethylcellulose MS were statistically analysed using analysis of variance, ANOVA. 
The data obtained was then used to generate predictor equations for domperidone concentration 
and polymer concentration. The results of ANOVA are given in Table 1a. 
Percentage drug entrapment of the MS showed a R² value of 0.999, indicating a good fit. Also, 
percent yield and particle size of the MS showed a R² value of 0.9997 and 0.9961 respectively 
indicating a good fit. 
Regression of the data resulted in the equations: 
Y1 = 48.67- 23.83X1- 5.33X2- 13.25X1X2 - 28.50X1
2 + 8.00X2
2     
Y2 = 89-2.17X1- 21.67X2- 56.0X1X2 - 64.5X1
2+ 35X2
2 
Y3 = 60-22.5X1- 14.5X2- 29.5X1X2 - 18.00X1
2+ 13.5X2
2     
Where dependent variables Y1 is the drug entrapment, Y2 is the particle size and Y3 is the percent 
yield of the domperidone loaded ethyl cellulose MS. Whereas X1 and X2 are the independent 
variables corresponding to amount of ethyl cellulose (% w/v) and amount of domperidone (% w/v) 
in MS respectively. 
 
b) Characterization of MS 
i)Appearance and Particle size 
The MS were white in color, spherical in shape and free flowing with rigid morphology. The MS 
were in the size range of 45-189 µm with mean particle size of 151 µm (Figure 2a). The particle 
size of MS was well within ≤ 200 µm limit and would thus avoid any gritty feeling in the mouth 
after disintegration.   It is well known that particle size above 200 µm causes rough mouth feel 
though threshold particle size within ODT required for feeling roughness has been determined to 
be >200μm because of the palatability of the exicipients like mannitol used in ODT25,41. 
ii) Calibration Curve of Domperidone 
Calibration curve of domperidone was prepared in 0.1 M HCl. Equation for calibration curve 
obtained was y = 0.0375x - 0.051;  and a R² value of 0.996 estabilished the linearity in the 
concentration range of 2-20 µg/ml. 
iii) Scanning Electron Microscopy 
The SEM studies revealed domperidone loaded MS were spherical in shape. However the surface 
of MS was rough with a porous texture (Figure 2b). This is in confirmation with earlier reports on 
MS prepared with ethyl cellulose polymer42,43. 
iv) Differential Scanning Calorimetry (DSC)   
The drug could be either dispersed in crystalline or amorphous form or dissolved in the polymeric 
matrix during the process of micro encapsulation. Any abrupt or drastic change in the thermal 
behavior of either the drug or polymer may indicate a possible drug-polymer interaction. DSC of 
domperidone MS (Figure 3) displayed characteristic, well recognizable endothermic peak of 
domperidone at the 2540C, temperature corresponding to the melting point of the pure drug 
indicating that the drug is compatible with the polymer and no significant transformation of the 
drug has occurred after processing44. There was no change in the melting endotherm of the polymer 
confirming absence of any drug polymer interaction. 
v) In-Vitro Drug Release 
Several techniques have been utilized to improve the dissolution of active pharmaceutical 
ingredient45.   It has been reported44 that the dissolution profile of domperidone pure drug in a 
acidic medium of pH 1.2 buffer showed drug to dissolve to the extent of 91% in 2 h, however, in 
an alkaline pH the dissolution of the drug was much slower, with as much as only 16% dissolved 
in 15 min. in buffer of pH 6.8. As maintenance of sink conditions is an important requirement of 
dissolution media and drug release from the microspheres is the desirable rate limiting factor,  
dissolution studies were performed in pH 1.2 buffer46. 
In-vitro release of domperidone from ethyl cellulose MS exhibited initial burst release with 23% 
of drug being released in 1 h. This is a common observation in the MS formulations due to the 
presence of drug particles on the surface of the MS. The burst effect seen during the in-vitro release 
from the MS was lower in case of MS prepared from higher concentration of the polymer47,48,.  
After the burst release, all the domperidone MS formulations showed sustained release of the drug 
up to 9 h. The best fit with the highest correlation coefficient was shown in Higuchi equation 
followed by first-order and then zero-order equation (Table 1b). High correlation observed in the 
Higuchi plot rather than first-order and zero-order models indicated matrix controlled drug release 
kinetics. Previously reported Zidovudine MS prepared using ethyl cellulose has shown similar 
release profile42,43.  
Orodispersible Sustained Release Tablet 
a) Physical Properties of the Tablet Blend 
Table 3 reports the evaluation of physical properties like bulk density, tap density, percent 
compressibility and Hausner ratio of blends ready for compression for all ODT-SR batches. 
According to literature49 powders with a percent compressibility between 5 and 18% are suitable 
for producing tablets and those with a Hausner ratio below 1.25 have good flowability. ODT-SR 
blends of all batches demonstrated a percent compressibility between 8.37 and 15.04 and a 
Hausner ratio below 1.25. Percent compressibility and Hausner ratio of ODT-SR blends suggests 
good compressibility for all formulations, except F5 and F7. The ODT-SR blend of all the batches 
also showed good flowability (angle of repose <30°), except batch F1 with an angle of 42.16°. The 
poor flowability of F1 may be attributed to the presence of only microcrystalline cellulose having 
filamentous particles as a diluent50. 
b) Evaluation of Orodispersible Sustained Release Tablet 
 The thickness of all the tablets was found in range of 2.37 to 2.41 mm and was within the 
prescribed limits (±5%)51.  All tablets were acceptable in terms of uniformity of mass35. Friability 
of all batches was less than 1% and hardness was found to be within the limits specified (35-40 N) 
for fast disintegrating tablets (Table 4).  
i) Disintegration Time 
As ODT-SR was formulated as compressed tablet ODT, crospovidone was used as 
superdisintegrant to provide quick disintegration of the tablet52. The time for disintegration for 
ODT is usually considered less than a minute53. However there is lack of globally harmonized 
nomenclature and disintegration criteria for ODTs. For example the European Pharmacopoeia35 
defines orodispersible dosage forms as having disintegration time of less than 3 min but US FDA 
guidelines for ODTs state that ODTs  should have in-vitro disintegration time of 30 seconds or 
less54,55. The ODT-SR formulations (FI-F7) disintergrated in less than a minute meeting the 
requirements of the European Pharmacopoeia, batch F4 with disintegration time of 21 seconds 
also met the more rigrous guidelines of US FDA (Table 4) and was selected for further studies. 
Spray-dried mannitol and microcrystalline cellulose in the ratio 1:1 in batch F4 contributed to its 
fast disintegration. The batch F6 containing a higher amount of spray-dried mannitol showed 
increased disintegration time. Increase in disintegration time may be due to the increase in the 
polyol quantity in the tablet formulations. As polyols are readily soluble in water, there exists a 
competition between spray-dried mannitol and Crospovidone for water penetrating into the tablet, 
consequently leading to poor swelling of Crospovidone with subsequent delay in disintegration. 
Disintegration time of tablets of batch F5 containing microcrystalline cellulose and spray-dried 
lactose in a 1:1 ratio was also slightly higher than F4, probably because of the formation of a sticky 
layer due to the dissolution of the lactose and subsequent hindrance in the further ingress of water 
into the tablet in accordance with the study of Khan et al56. 
ii) In-vitro Drug Release 
When the selected ODT-SR (F4) was placed in in-vitro release medium it disintegrated rapidly 
releasing the intact MS. The drug release from these MS was similar to that obtained prior to 
compression and confirmed the maintenance of integrity of the MS on compression. As observed 
in the dissolution profile of MS, there was burst release of 23 % in 1 h, 50 % of the drug released 
in 2.26 h and 90 % of drug was released in 7.53 h. The drug release typically followed Higuchi 
square root kinetics with sustained drug release up to 9 h. This is totally in contrast with 
conventional orodispersible tablets (OC1) of domperidone which released 100 % of the drug in 10 
min and while the conventional domperidone tablets (OC2) released the drug in 2 h (Figure 4).  
iii) Stability  
Stability studies of ODT-SR (F4)  stored in an aluminium package under normal temperature and 
in a controlled stability chamber at 40 ºC and 75% RH  for 12 weeks, showed no significant 
changes in the domperidone content, drug release profile and color of the tablets. The content of 
domperidone was stable ranging from 97.66% to 98.78% during 12 weeks after storage at 25ºC 
and 60% RH , or from 98.24% to 98.88% during the same period after storage at 40ºC and 75% 
RH. Drug release profile of  F4 in terms of t10% , t50% and t90% was found in the range of 0.29 h to 
0.34 h , 2.24 h to 2.34 h and 7.53 h to 7.65 h respectively, during 12 weeks after storage at 25ºC 
and 60% RH and 0.34 h to 0.39 h , 2.22h to 2.68 h and 7.65 h to 7.81 h respectively, for 12 weeks 
after storage at 40ºC and 75% RH. 
iv) In-vivo Pharmacokinetic Studies of Domperidone 
Domperidone after oral administration in Wistar rat was absorbed rapidly from the conventional 
formulation giving a mean peak plasma concentration of 23.53 µg/ml within 4 h after treatment. 
Domperidone is known to undergo rapid and complete absorption from gut57,58. The drug plasma 
concentration declined rapidly thereafter with no drug being detected beyond 8 h. Domperidone  
undergoes rapid first pass metabolism though renal clearance is low59. Conventional formulation 
showed much shorter t1/2 as compared to that reported for humans. This is  consistent with an 
earlier study showing t1/2  of  1.40 ± 0.02 h for domperidone in rat
60.  
The ODT-SR (F4) of domperidone gave a mean peak plasma concentration of 20.4266 µg/ml 10 
h post administration (Figure 5). The ODT-SR maintained drug concentration in plasma up to 24 
h as compared to the conventional formulation, where the drug levels could no longer be detected 
after 8 h. It was also observed that MRT of the domperidone ODT-SR (11.16 h) was 2.9 times 
higher than that of the conventional marketed formulation (3.86 h) indicating prolonged residence 
in the body. Thus, significant sustained drug plasma levels were observed with ODT-SR indicating 
rate controlled release of domperidone from the MS after oral administration. when compared to 
the marketed formulation (Table 5). 
The mean AUC of the ODT-SR was 415.3 µg.h/ml, which was almost 3 times greater than AUC 
obtained with conventional marketed domperidone tablet indicating higher bioavailability of the 
ODT-SR. Statistical analysis by ANOVA revealed significant difference between two groups in 
the values of Cmax, Tmax, AUC,  and MRT  as revealed by the F value at 5 DF and P < 0.05.      
Conclusion 
The present platform technology combines the convenience of fast dissolving orodispersible 
dosage form and performance of controlled release delivery system. Not only would it address 
some of the problems encountered in administration of drugs to the pediatric and elderly patient, 
which constitutes a large proportion of the world’s population but also has added therapeutic 
advantages of less frequent administration, patient compliance, predictable and reproducible drug 
release, steady drug plasma levels with better treatment efficiency.  
The ODT-SR of domperidone disperses readily within 21 sec without exceeding the disintegration 
time limitation specified in the US FDA guidelines for ODT ( < 30 sec) into MS of  size range of 
45-189 µm, which released the drug in sustained manner over the period of 9 h. The in-vivo 
pharmacokinetic study in Wistar rats revealed that the ODT-SR maintained drug concentration in 
plasma up to 24 h with three times higher bioavailability. Statistical analysis by ANOVA revealed 
significant difference between marketed conventional tablet of domperidone and ODT-SR. Thus 
this product has convenience of orodispersible dosage form and a benefits of sustained release 
system combined in one. The developed technology is simple and can be easily scaled up and thus, 
holds enormous potential for commercial exploitation. 
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Translation of coded levels in actual values 
Coded level                               -1         0         1 
X1: Ethyl Cellulose (% w/v)    1.5        2         2.5 








































































Table I (b):  Goodness of fit to mathematical drug release models applied to drug release kinetics of 
MS 
 







































































































































































































































 Table V:  Pharmacokinetic parameters of domperidone in rat after oral 
administration of conventional marketed  tablet and developed ODT-SR (F-4) 
 
 




  (n=6) 
Mean±SD 
  P values 
Cmax (µg/ml) 23.53±2.45 20.43±1.98 0.037 
Tmax (h) 4±0.395 10±1.095 0.000 
t½ (h) 1.07±0.056 3.01±0.0215 0.000 
AUC0-24h  (µg.h/ml) 136.9 ±13.9 415.3 ±31.76 0.000 
AUMC0-24h (µg.h²/ml) 528.7±43.5 4639±387 0.000 
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Figure 1: Chemical structure of domperidone 
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Figure 3: Differential scanning thermograms of (a) pure domperidone (b) ethyl cellulose and (c) 
domperidone microspheres 
  
Figure 4: Comparative dissolution profile of optimized orodispersible sustained release tablet of 
domperidone (F4), marketed domperidone orodispersible tablet (OC1) and marketed domperidone 
conventional tablet (OC2) 
 
 
Figure 5: Plasma concentration vs. time plot of domperidone after oral administration  of marketed 
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